Practitioner's Docket No. 701586-54555

PATENT

IN THE UNITED STATES RECEIVING OFFICE

PCT/US2004/033178	08.10.2004 08 October 2004	09.10.2003 09 October 2003	
International	International	International Earliest	
Application Number	Filing Date	Priority Date	

TITLE OF INVENTION: METHODS AND COMPOSITIONS USING ADIPONECTIN FOR TREATMENT OF CARDIAC DISORDERS AND FOR STIMULATION OF ANGIOGENESIS

APPLICANT(S) FOR EO/DO:

The Trustees of Boston University

INVENTOR(S)/APPLICANT(S) FOR US: Kenneth WALSH et al.

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV653005045US in an envelope andressed to MAIL STOP

Commissioner for Patents, P. Ø. Box

Date: April 6, 2006

MAIL STOP PCT **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1 and C1-C5 cited in the attached Forms PTO/SB/08 a and b.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed: within three (3) months of the Filing Date or before the mailing date __X__ (1) of the First Office Action on the merits; or within three months of the mailing date of the PCT International (2) Search Report; or

100/457468/2:8632 1AP9 Rec'd PCT/FTO 06 APR 2006

International Application Number: PCT/US2004/033178 International Filing Date: 08 October 2004 International Earliest Priority Date: 09 October 2003 Page 2 of 2 after the period defined in (1) but before the mailing date of a Final (3) Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or after the mailing date of a Final Rejection or Notice of Allowance (4) but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein. A copy of the International Search Report is enclosed herewith. It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08a and b be made of record in this application. Copies of these documents (CHECK ONE): are enclosed herewith; or have been cited in the parent application, and are thus not being resubmitted herein. FEE AUTHORIZATION The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Respectfully submitted,

Ronald I. Eisenstein (Reg. No. 30,628) J. Amelia Feulner (Reg. No. 58,039)

NIXON PEABODY LLP 100 Summer Street Boston, MA 02110-2131

(617) 345-6054

Date: April 6, 2006

10-/574828 1632 1632 APR 2006

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Applica
L.A. Fill
First N.

of

2

Sheet

1

Complete if Known				
To be assigned				
October 8, 2004				
Kenneth Walsh				
To be assigned				
To be assigned				
701586-54555				

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
	1	US-			
	-	US-			

	FC	REIGN PATENT I	DOCUMENTS		
Cite No. 1	Foreign Patent Document Kind Code ³	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Bl	WO 2004/105786	12-09-2004	Pharmagene Laboratories LTD et al.		
					-
			-		
				<u> </u>	
	No. I	Cite No. 1 Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (if known)	Cite No. 1 Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (if known) Publication Date MM-DD-YYYY	No. 1 Country Code ³ Number ⁴ Kind Code ³ MM-DD-YYYY Applicant of Cited Document	Cite No. 1 Country Code ³ Number ⁴ Country Code ³ Number ⁴ Kind Code ³ (if known) Relevant Passages or Relevant Figures Appear Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document Figures Appear Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

 Examiner Signature
 /Michael Wilson/ (09/08/2008)
 Date Considered
 09/08/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222 uspto gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

0574828 - GAU: 1632

Substitute for form 1449A/PTO To be assigned Application Number INFORMATION DISCLOSURE October 8, 2004 I.A. Filing Date STATEMENT BY APPLICANT Kenneth Walsh First Named Inventor (use as many sheets as necessary) To be assigned Art Unit To be assigned Examiner Name of Attorney Docket Number 2 701586-54555 Sheet 2

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.W./	C1	DIEZ, Juan J. et al.; European Journal of Endocrinology; 148:293-300 (2003)	
/M.W./	C2	KUBOTA, Naoto et al.; The Journal of Biological Chemistry; 277(29):25863-25866 (July 19, 2002)	
/M.W./	C3	MATSUDA, Morihiro et al.; The Journal of Biological Chemistry; 277(40):37487-37491 (October 4, 2002)	
/M.W.	C4	OUCHI, Noriyuki et al.; The Journal of Biological Chemistry; 279(2):1304-1309 (January 9, 2004)	
/M.W./	C5	SHIBATA, Rei et al.; The Journal of Biological Chemistry; 279(27):28670-28674 (July 2, 2004)	
	_		

Examine	/Michael Wilson/ (09/08/2008)	Date	09/08/2008
Signature		Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.